SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 150.39 |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 112.27 |
| Book Value / Share | 1.13 |
| Price / Book | n/a |
| NCAV ($M) | 53.35 |
| NCAV / Share | 0.54 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.43 |
| Return on Assets (ROA) | -0.30 |
| Return on Equity (ROE) | -0.35 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.71 |
| Current Ratio | 1.71 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 171.99 |
| Assets | 230.91 |
| Liabilities | 118.64 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 27.31 |
| Operating Income | -52.38 |
| Net Income | -50.92 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 65.84 |
| Cash from Investing | -105.29 |
| Cash from Financing | -1.12 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | AFFiRiS AG | 6.50 | -2.28 | |
| 13G/A | Biotechnology Value Fund L P | 19.70 | 33.98 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 32,370 | 119,894 | 27.00 | |
| 27,813 | 112,631 | 24.69 | |
| 16,626 | 175,043 | 9.50 | |
| 38,165 | 144,775 | 26.36 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ACET – Adicet Bio, Inc. | ACRV – Acrivon Therapeutics, Inc. |
| ADMA – ADMA Biologics, Inc. |
Financial data and stock pages provided by
Fintel.io